Production (Stage)
Kezar Life Sciences, Inc.
KZR
$4.43
$0.030.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 22.40% | 17.80% | -9.10% | -19.43% | -36.17% |
| Total Depreciation and Amortization | -3.37% | -2.44% | 110.93% | 57.98% | 23.35% |
| Total Amortization of Deferred Charges | 47.50% | 10.21% | 9.57% | 9.82% | 10.09% |
| Total Other Non-Cash Items | -28.66% | -33.01% | -3.06% | 40.93% | 15.91% |
| Change in Net Operating Assets | -135.39% | -127.62% | 278.08% | 202.14% | 158.22% |
| Cash from Operations | 18.06% | 9.10% | 2.78% | -5.86% | -25.99% |
| Capital Expenditure | 97.55% | 98.40% | 99.12% | 94.77% | -6.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -9.53% | 3.35% | 103.06% | 6,951.90% | 680.87% |
| Cash from Investing | -7.87% | 5.76% | 114.04% | 2,194.73% | 617.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.72% | -83.86% | -89.40% | -87.12% | -99.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -348.14% | -83.86% | -89.40% | -87.12% | -99.39% |
| Foreign Exchange rate Adjustments | -1,800.00% | -3,050.00% | 4,900.00% | 140.74% | 103.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 228.19% | 226.05% | 122.03% | 100.22% | -11.44% |